Phaseline

Companies › Kedrion

Kedrion: clinical trials, targets and expected readouts

2 active drug programs in 3 registered trials: 3 Phase 3; Neurology, Hematology, Immunology; next expected readout Dec 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Kedrion IVIG 10%
Intravenous immunoglobulin (polyclonal IgG)
–Phase 3Primary Immunodeficiency Disease; Chronic Primary Immune Thrombocytopenia (ITP)Dec 2026
KIg10 (QIVIGY)
Intravenous Human Immune Globulin 10%
–Phase 3Chronic Inflammatory Demyelinating PolyneuropathyDec 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT04944979Kedrion IVIG 10%Phase 3Primary Immunodeficiency DiseaseImmunologyDec 2026
NCT07059000Kedrion IVIG 10%Phase 3Chronic Primary Immune Thrombocytopenia (ITP)HematologyDec 2026
NCT06752356KIg10 (QIVIGY)Phase 3Chronic Inflammatory Demyelinating PolyneuropathyNeurologyDec 2027

Targets

No annotated target.

Companies with the same targets

–

Companies built like this

Incepta Pharmaceuticals Longbio Pharma Sandoz Neurona Therapeutics Doron Therapeutics

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.